MIDDLESEX GASES TECHNOLOGIES, INC.
PharmaMIDDLESEX GASES TECHNOLOGIES, INC. is a pharmaceutical company with 1 FDA-approved products.
MIDDLESEX GASES TECHNOLOGIES, INC.'s Key Drugs
MIDDLESEX GASES TECHNOLOGIES, INC.'s core commercial portfolio centers on CARBON DIOXIDE, USP — its most strategically important drugs approved in the last 15 years.
MIDDLESEX GASES TECHNOLOGIES, INC.'s Recent FDA Approvals
MIDDLESEX GASES TECHNOLOGIES, INC. secured 6 new FDA approvals for novel drugs (NDA/BLA) in the last two years.
MIDDLESEX GASES TECHNOLOGIES, INC.'s Therapeutic Areas
Disease areas where MIDDLESEX GASES TECHNOLOGIES, INC. has approved drugs and an active pipeline. Weighted by commercial stage — approved drugs count most, then late-stage trials.
MIDDLESEX GASES TECHNOLOGIES, INC. Pipeline Snapshot
Active clinical trials for MIDDLESEX GASES TECHNOLOGIES, INC. across all therapeutic areas, from ClinicalTrials.gov.
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • CARBON DIOXIDE, USP leads revenue
- • Drug-level revenue analysis
Trial Catalysts
- • Active trial monitoring
- • Phase 3 readout tracking
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Revenue forecasts • Trial milestones • Patent risk modeling
Active (1)
Discontinued (0)
Company Info
- First Approval
- 2021-10-18
- Latest
- 2021-10-18
- Applications
- 1